Senvest Management’s Rein Therapeutics RNTX Stock Holding History

Senvest Management’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.28M	Buy	1,230,895 +1,000,000	+433%	+$1.21M	0.04%	53
2026 Q1	$300K	Hold	230,895	–	–	0.01%	49
2025 Q4	$268K	Hold	230,895	–	–	0.01%	52
2025 Q3	$264K	Hold	230,895	–	–	0.01%	52
2025 Q2	$323K	Hold	230,895	–	–	0.01%	53
2025 Q1	$409K	Hold	230,895	–	–	0.02%	42
2024 Q4	$531K	Hold	230,895	–	–	0.02%	58
2024 Q3	$801K	Hold	230,895	–	–	0.03%	49
2024 Q2	$576K	Hold	230,895	–	–	0.02%	47
2024 Q1	$1.3M	Buy	+230,895	New	+$1.11M	0.05%	51

Other funds holding RNTX

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Senvest Management's RNTX Position: Q2 2026 in Review

Senvest Management increased its Rein Therapeutics (RNTX) stake by 433% in Q2 2026, buying an estimated $1.21M and bringing the position to 1,230,895 shares worth $1.28M. The position accounts for 0.04% of the portfolio, ranked #53.

Senvest Management first reported a position in RNTX in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.3M in Q1 2024. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

Senvest Management held 1,230,895 shares of Rein Therapeutics worth $1.28M as of Q2 2026.
Senvest Management bought 1,000,000 Rein Therapeutics shares in Q2 2026, an estimated $1.21M.
Rein Therapeutics made up 0.04% of Senvest Management's portfolio in Q2 2026, its #53 holding.
Senvest Management first reported a position in Rein Therapeutics in Q1 2024 and has held it in 10 quarters since.
Senvest Management's Rein Therapeutics position peaked at $1.3M in Q1 2024.
60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Senvest Management's 13F filing for Q2 2026, filed 14 Aug 2026.